Sarepta Therapeutics Extends Debt Maturities with New Notes
TipRanks (Fri, 19-Dec 5:03 PM ET)
Evercore ISI Remains a Hold on Sarepta Therapeutics (SRPT)
TipRanks (Thu, 18-Dec 10:36 AM ET)
Sarepta’s $291 Million Note Refinancing Extends Debt Maturity and Bolsters Financial Flexibility
Market Chameleon (Thu, 11-Dec 3:12 AM ET)
Business Wire (Thu, 11-Dec 7:00 AM ET)
Business Wire (Tue, 25-Nov 8:58 AM ET)
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
Business Wire (Mon, 24-Nov 7:30 AM ET)
Business Wire (Mon, 24-Nov 7:30 AM ET)
PRNewswire (Thu, 20-Nov 10:00 AM ET)
Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information
Business Wire (Fri, 14-Nov 2:54 PM ET)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Sarepta Therapeutics trades on the NASDAQ stock market under the symbol SRPT.
As of December 23, 2025, SRPT stock price climbed to $21.89 with 599,782 million shares trading.
SRPT has a beta of 1.44, meaning it tends to be more sensitive to market movements. SRPT has a correlation of 0.05 to the broad based SPY ETF.
SRPT has a market cap of $2.29 billion. This is considered a Mid Cap stock.
Last quarter Sarepta Therapeutics reported $399 million in Revenue and -$.13 earnings per share. This beat revenue expectation by $56 million and exceeded earnings estimates by $.33.
In the last 3 years, SRPT traded as high as $173.25 and as low as $10.42.
The top ETF exchange traded funds that SRPT belongs to (by Net Assets): IJR, XBI, VTI, VB, FBT.
SRPT has underperformed the market in the last year with a price return of -81.6% while the SPY ETF gained +17.1%. However, in the short term, SRPT had mixed performance relative to the market. It has outperformed in the last 3 months, returning +17.4% vs +3.0% return in SPY. But in the last 2 weeks, SRPT shares have been beat by the market, returning +0.1% compared to an SPY return of +0.5%.
SRPT support price is $20.24 and resistance is $22.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRPT shares will trade within this expected range on the day.
